

18 August 2015

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

Market Announcement – Closure of GXG Markets

The Directors of iQnovate Limited (NSX:IQN) (the Company) advise that on 6 July 2015, GXG Markets announced its decision to voluntarily relinquish its Danish Market Operator licenses. The Danish Supervisory Authority has subsequently accepted the surrender of GXG's licences. GXG Markets have since announced the closure of its market and trading facilities with effect from 1700 CET on 18 August 2015. As a result, the Company's securities will no longer be available for quotation on the GXG market. The Company's securities remain available for quotation and trade on the NSX and OTCQB marketplace.



Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE iQnovate Limited

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.